Neogenomics Inc. Corporate Restructuring Announcement
Date: 24 October 2026Ticker: NEO (NASDAQ)
1. Executive Summary
Neogenomics Inc. (NEO) announced that its subsidiary, Algo8, will be transferred to a newly created entity, Algo8 AI Inc. The transaction is scheduled to conclude on 21 June 2026. Upon completion, Algo8 AI Inc. will list on the Canadian Securities Exchange under the symbol AIOS. The restructuring involves an exchange of existing shares for new shares and the transfer of all outstanding Algo8 equity to the new issuer.
2. Transaction Details
| Item | Description |
|---|---|
| Parties Involved | Neogenomics Inc., Algo8, GoGo, and Spin Co. |
| Share Exchange | Existing Algo8 shares will be exchanged for shares of Algo8 AI Inc. |
| Equity Transfer | All outstanding Algo8 equity will be transferred to Algo8 AI Inc. |
| Completion Date | 21 June 2026 |
| Listing Venue | Canadian Securities Exchange (symbol: AIOS) |
3. Financial Outlook and Use of Proceeds
Neogenomics has provided a working‑capital outlook for the next twelve months, outlining planned use of funds in the following areas:
- Technical Team Development – recruitment and retention of AI and data‑science talent.
- Product Development – enhancement of AI‑driven diagnostic tools.
- Marketing – expansion of commercial outreach to new clinical partners.
- General Administration – ongoing operational support for the new entity.
4. Risk Disclosure
The filing includes audited financial statements for all parties and a detailed risk disclosure covering:
- High‑risk nature of AI‑driven business activities.
- Regulatory compliance requirements in the healthcare sector.
- Market uncertainties related to competitive dynamics and pricing pressures.
5. Market Performance – 24‑Hour Summary
| Stock | Change | Current Price (USD) | Market Cap (USD) |
|---|---|---|---|
| Neogenomics (NEO) | +1.22 % | 17.01 | 2.10 bn |
| Mbx Biosciences (MBX) | +1.94 % | 55.18 | 2.50 bn |
| Resideo (REZI) | +2.83 % | 17.30 | 2.50 bn |
| Customers (CUBI) | +2.07 % | 76.20 | 2.50 bn |
| Hayward (HAYW) | +2.63 % | 12.09 | 2.50 bn |
| Gcm Grosvenor (GCMG) | +1.94 % | 12.61 | 2.50 bn |
Neogenomics specific metrics
- Current share price: 17.01 USD (as of 04:53 PM Central Europe, 21 Oct 2026).
- Shares outstanding: 128.5 million.
- Market capitalization: 2.10 bn USD.
- Volume traded (last 24 h): 18.3 million USD.
- Price change since last month‑end: –14.37 %.
- 200‑day simple moving average: 12.61 USD.
- 52‑week high: 20.15 USD (10 Jun 2026).
- 52‑week low: 7.07 USD (30 Mar 2026).
6. Company Overview
Neogenomics Inc. operates a network of clinical laboratories that specialize in cancer genetics diagnostic testing services, including cytogenetics, fluorescence in‑situ hybridization (FISH), flow cytometry, morphology, anatomic pathology, and molecular genetic testing. Services are provided to pathologists, oncologists, urologists, and hospitals. The company was founded in 1999 and its IPO was conducted on 2 November 1999. Its stock is listed on the Nasdaq.
7. Regulatory Filings and Corporate Actions
- Resideo (REZI): Filed Rule 144 notice for a sale of common shares by an officer; scheduled sale mid‑October 2026.
- Customers (CUBI): Announces upcoming quarterly results conference on 22 Oct 2026.
- Hayward (HAYW): Filed Form 4 for insider sale by Susan Canning, reducing her stake to just over one‑sixth of outstanding shares.
No additional corporate actions or market‑impact events are disclosed for the other referenced stocks.